Tumor Genetics Influence Efficacy of Protein-Degrading Cancer Therapies
Researchers at the University of Edinburgh have found that the genetic mechanism driving oncogene activation can significantly impact how effectively tumors respond to protein-degrading therapies, known as PROTACs (proteolysis-targeting chimeras). The study, published in Cell Chemical Biology, used β-catenin as a model oncogenic protein. They discovered that tumors where oncogenes are activated by mutations that increase protein stability are more susceptible to degradation. However, if high protein levels are due to increased protein production (e.g., through gene amplification), the PROTACs may be less effective because cells continuously replace the degraded protein. This suggests that a detailed understanding of tumor genetics and how protein targets become activated in cancer is crucial for predicting the activity of protein degraders. The findings highlight that simply measuring the percentage of protein degradation (Dmax) might not tell the whole story, as the absolute amount of residual oncogenic p... 
